Puneet Talwar

Puneet Talwar

Auto-generated profile, based on publicly available information

Puneet Talwar

GIGA-CRC Human Imaging, University of Liège

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2021 in Clinical Neuroradiology
Verified
Journal Article
Closed access
PDF file
PTPuneet Talwar
Puneet Talwar
SKSuman Kushwaha
Suman Kushwaha
MCMonali Chaturvedi
Monali Chaturvedi
VMVidur Mahajan
Vidur Mahajan

15 March 2014 in BMC Genomics
Verified
Journal Article
Open access
PDF file
PTPuneet Talwar
Puneet Talwar
YSYumnam Silla
Yumnam Silla
SGSandeep Grover
Sandeep Grover
MGMeenal Gupta
Meenal Gupta
RARachna Agarwal
Rachna Agarwal
RKRitushree Kukreti
Ritushree Kukreti
Background: Alzheimer’s disease (AD) is one of the leading genetically complex and heterogeneous disorder that is influenced by both genetic and environmental factors. The underlying risk factors remain largely unclear for this heterogeneous disorder. In recent years, high throughput methodologies, such as genome-wide linkage analysis (GWL), genome-wide association (GWA) studies, and genome-wide expression profiling (GWE), have led to the identification of several candidate genes associated with AD. However, due to lack of consistency within their findings, an integrative approach is warranted. Here, we have designed a rank based gene prioritization approach involving convergent analysis of multi-dimensional data and protein-protein interaction (PPI) network modelling. Results: Our approach employs integration of three different AD datasets- GWL,GWA and GWE to identify overlapping candidate genes ranked using a novel cumulative rank score (SR) based method followed by prioritization using clusters derived from PPI network. SR for each gene is calculated by addition of rank assigned to individual gene based on either p value or score in three datasets. This analysis yielded 108 plausible AD genes. Network modelling by creating PPI using proteins encoded by these genes and their direct interactors resulted in a layered network of 640 proteins. Clustering of these proteins further helped us in identifying 6 significant clusters with 7 proteins (EGFR, ACTB, CDC2, IRAK1, APOE, ABCA1 and AMPH) forming the central hub nodes. Functional annotation of 108 genes revealed their role in several biological activities such as neurogenesis, regulation of MAP kinase activity, response to calcium ion, endocytosis paralleling the AD specific attributes. Finally, 3 potential biochemical biomarkers were found from the overlap of 108 AD proteins with proteins from CSF and plasma proteome. EGFR and ACTB were found to be the two most significant AD risk genes. Conclusions: With the assumption that common genetic signals obtained from different methodological platforms might serve as robust AD risk markers than candidates identified using single dimension approach, here we demonstrated an integrated genomic convergence approach for disease candidate gene prioritization from heterogeneous data sources linked to AD.

9 September 2015 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
PTPuneet Talwar
Puneet Talwar
JSJuhi Sinha
Juhi Sinha
SGSandeep Grover
Sandeep Grover
CRChitra Rawat
Chitra Rawat
SKSuman Kushwaha
Suman Kushwaha
RKRitushree Kukreti
Ritushree Kukreti

1 September 2010 in Biochimie
Verified
Journal Article
Closed access
SGSandeep Grover
Sandeep Grover
KBKiran Bala
Kiran Bala
SSSangeeta Sharma
Sangeeta Sharma
MGM. Gourie-Devi
M. Gourie-Devi
RBRuchi Baghel
Ruchi Baghel
RKRitushree Kukreti
Ritushree Kukreti

6 July 2010 in Pharmacogenomics
Verified
Journal Article
Closed access
SGSandeep Grover
Sandeep Grover
MGMandaville Gourie-Devi
Mandaville Gourie-Devi
RBRuchi Baghel
Ruchi Baghel
SSSangeeta Sharma
Sangeeta Sharma
KBKiran Bala
Kiran Bala
RKRitushree Kukreti
Ritushree Kukreti
The first-line antiepileptic drugs, although affordable and effective in the control of seizures, are associated with adverse drug effects, and there is large interindividual variability in the appropriate dose at which patients respond favorably. This variability may partly be explained by functional consequences of genetic polymorphisms in the drug-metabolizing enzymes, such as the CYP450 family, microsomal epoxide hydrolase and UDP-glucuronosyltransferases, drug transporters, mainly ATP-binding cassette transporters, and drug targets, including sodium channels. The purpose of this study was to determine the allele and genotype frequencies of such genetic variants in patients with epilepsy from North India administered first-line antiepileptic drugs, such as phenobarbitone, phenytoin, carbamazepine and valproic acid, and compare them with worldwide epilepsy populations. SNP screening of 19 functional variants from 12 genes in 392 patients with epilepsy was carried out, and the patients were classified with respect to the metabolizing rate of their drug-metabolizing enzymes, efflux rate of drug transporters and sensitivity of drug targets. A total of 16 SNPs were found to be polymorphic, and the allelic frequencies for these SNPs were in conformance with Hardy-Weinberg equilibrium. Among all the polymorphisms studied, functional variants from genes encoding CYP2C19, EPHX1, ABCB1 and SCN1A were highly polymorphic in North Indian epilepsy patients, and might account for differential drug response to first-line antiepileptic drugs. Interethnic differences were elucidated for several polymorphisms that might be responsible for differential serum drug levels and optimal dose requirement for efficacious treatment.

1 January 2016 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
PTPuneet Talwar
Puneet Talwar
JSJuhi Sinha
Juhi Sinha
SGSandeep Grover
Sandeep Grover
RARachna Agarwal
Rachna Agarwal
SKSuman Kushwaha
Suman Kushwaha
RKRitushree Kukreti
Ritushree Kukreti